Exhibit 107
Calculation of Filing Fee Tables
Schedule TO
POINT BIOPHARMA GLOBAL INC.
(Name of Subject Company (issuer))
YOSEMITE FALLS ACQUISITION CORPORATION
(Offeror)
a wholly-owned subsidiary of
ELI LILLY AND COMPANY
(Parent of Offeror)
(Names of Filing Persons (identifying status as offeror, issuer or other person))
Table 1-Transaction Valuation
| Transaction Valuation* | Fee rate | Amount of Filing Fee** | ||||
Fees to Be Paid | $1,376,985,669.38 | 0.0001476 | $203,243.08 | |||
Fees Previously Paid | $0 | $0 | ||||
Total Transaction Valuation | $1,376,985,669.38 | |||||
Total Fees Due for Filing | $203,243.08 | |||||
Total Fees Previously Paid | $0 | |||||
Total Fee Offsets | $0 | |||||
Net Fee Due | $203,243.08 | |||||
| * | Estimated solely for purposes of calculating the amount of the filing fee only. The transaction valuation was calculated by adding (a) the product of (i) $12.50, the purchase price per share (the “Offer Price”) of POINT Biopharma Global Inc. (“POINT”) common stock, par value $0.0001 per share (each such share, a “Share”), net to the stockholder in cash, without interest and less any applicable tax withholding, and (ii) 105,831,891 Shares issued and outstanding; (b) the product of (i) 8,511,642 Shares issuable pursuant to outstanding options with an exercise price less than the Offer Price and (ii) $6.14, the difference between the Offer Price and $6.36, the weighted average exercise price for such options; (c) the product of (i) 146,044 Shares subject to outstanding performance stock units and (ii) the Offer Price. The calculation of the filing fee is based on information provided by POINT as of October 9, 2023. |
| ** | The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #1 for fiscal year 2024 beginning on October 1, 2023, issued August 25, 2023, by multiplying the transaction value by 0.0001476. |
